BioMarCare

Company Overview

Snapshot

Founded in January 2002, BioMarCare had 1–10 employees. The company raised $1.9M across three funding rounds from two investors. In March 2012, BioMarCare secured a Seed round from Micromedic.

Business overview

BioMarCare specializes in developing tumor biomarker technologies for the early diagnosis of cancer. The company utilizes a multi-biomarker panel approach to create molecular blood tests and tissue-based diagnostic (IHC) tests, aiming for high specificity and sensitivity in cancer detection. Its product, Colon-MarCarePlex, is designed as an accurate, patient-friendly colorectal cancer screening test that measures gene expression biomarkers. Additionally, BioMarCare's mCRC-STRAT is a semi-quantitative IHC assay that predicts patient responses to drugs targeting the epidermal growth factor receptor. The company operates within the Health Tech & Life Sciences sector, focusing on Digital Medical Diagnostics and serving the healthcare industry, particularly laboratories.

Company Intelligence Q&A

What is BioMarCare's primary focus?

BioMarCare focuses on developing tumor biomarker technologies for the early diagnosis of cancer, utilizing multi-biomarker panel approaches for molecular blood tests and tissue-based diagnostic tests.

What is Colon-MarCarePlex?

Colon-MarCarePlex is BioMarCare's molecular assay (qRT-PCR) designed as an accurate, patient-friendly colorectal cancer screening test. It measures the expression of several genes to detect advanced adenoma polyps and early-stage colorectal cancer.

What is mCRC-STRAT?

mCRC-STRAT is BioMarCare's semi-quantitative IHC assay that uses a protein biomarker combination to predict patient responses to drugs targeting the epidermal growth factor receptor. This product is being developed in collaboration with a U.S. partner.

When was BioMarCare founded?

BioMarCare was founded in January 2002.